NASDAQ: ZURA

Zura Bio Limited

Healthcare | Biotechnology

No licensed closing price on file for ZURA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Zura Bio Limited (NASDAQ: ZURA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:13 UTC.

What Zura Bio Limited does

This company is a clinical-stage biotechnology firm developing medicines for autoimmune and inflammatory diseases with high unmet medical need. It has in-licensed three product candidates: tibulizumab, a bispecific antibody targeting two immune pathways; crebankitug, targeting interleukin-7 receptor; and torudokimab, targeting interleukin-33. The company is currently running two Phase 2 clinical trials of tibulizumab—one in hidradenitis suppurativa and one in diffuse cutaneous systemic sclerosis—each with optional extensions.

Summarized from Zura Bio Limited’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for ZURA are available in Oxford Ledge.
Open ZURA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-22

Most recent filed transactions — June 2026:

2026-06-22DirectorShare Option (Right to Buy)Award51,000—
2026-06-22DirectorShare Option (Right to Buy)Award51,000—
2026-06-22DirectorShare Option (Right to Buy)Award51,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

MONTANOVA CAPITAL, LLC9,443,001$55.71M+4.2%
Venrock Adviser, LLC6,434,990$37.97M0.0%
MPM BIOIMPACT LLC4,472,843$26.39MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-04-23Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-12-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-10-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ZURA and 5,000+ tickers.

Create a free account — keep ZURA

For your agent

GET /api/data?ticker=ZURA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt